• Halozyme Therapeutics average return on tangible equity for 2023 was -29.08, a 87.28% increase from 2022.
• Halozyme Therapeutics average return on tangible equity for 2022 was -228.62, a 205.46% decline from 2021.
• Halozyme Therapeutics average return on tangible equity for 2021 was 216.78, a 1148.73% decline from 2020.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.